FMP
Qualigen Therapeutics, Inc.
QLGN
NASDAQ
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
3.06 USD
0 (0%)
About
ceo
Mr. Kevin A. Richardson II
sector
Healthcare
industry
Biotechnology
website
https://www.qualigeninc.comexchange
NASDAQ
Description
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
CIK
0001460702
ISIN
US74754R2022
CUSIP
74754R103
Address
2042 Corte Del Nogal
Phone
760 918 9165
Country
US
Employee
4
IPO Date
Jun 23, 2015
Key Executives
Name
Title
Pay
Year Born
Mr. Michael S. Poirier
Chief Operating Officer
632.7k
1956
Mr. Christopher L. Lotz
Vice President of Finance & Corporate Se...
578.55k
1965
Mr. Robert W. Campbell Becher
President & Director
0
1971
Mr. Kevin A. Richardson II
Interim Chief Executive Officer, Interim...
0
1968
As of December 31, 2024, the total employee count stands at 4, with compensation values reflecting the last fiscal year ending on that date. Pay encompasses salary, bonuses, etc., All figures are in USD.
